Updated: Dec 7, 2022
Welcome to Cannabis Conclusions, a unique educational series from Higher Learning LV that is targeted at hemp and cannabis industry professionals. This series provides readers with the conclusion section from important modern peer-reviewed research studies.
A December 2019 study entitled "Antioxidative and Anti-Inflammatory Properties of Cannabidiol" that was published in the journal Antioxidants reviewed "review the main biological effects of CBD, and its synthetic derivatives, focusing on the cellular, antioxidant, and anti-inflammatory properties of CBD."
The study reported that it summarized "the chemical and biological effects of CBD and its natural and synthetic derivatives."
The study reported that it summarized "the chemical and biological effects of CBD and its natural and synthetic derivatives." It noted a focus on "the antioxidant and anti-inflammatory effects of CBD and its derivatives, bearing in mind the possibilities of using this phytocannabinoid to protect against oxidative stress and the consequences associated with oxidative modifications of proteins and lipids." The researchers noted that CBD has shown an acceptable safety profile and "a good side effect profile in many clinical trials."
"Oxidative stress resulting from overproduction of ROS is a key element of the immune system’s response to combat pathogens and initiates tissue repair. However, metabolic modifications resulting from overproduction of ROS also have many negative aspects and lead to the development and/or exacerbation of many diseases.
"It is believed that the endocannabinoid system, which includes G-protein coupled receptors and their endogenous lipid ligands, may be responsible for the therapeutic modulation of oxidative stress in various diseases. In this context, the phytocannabinoid cannabidiol, which was identified several decades ago and may interact with the cannabinoid system, is a promising molecule for pharmacotherapy.
"Relatively recently, multidirectional biological effects have been demonstrated in various preclinical models, including the antioxidant and anti-inflammatory effects of cannabidiol. In the context of the above data, CBD seems to be more preferred than other compounds from the phytocannabinoid group. Regardless of the beneficial pharmacological effects of CBD itself, if this compound is present in the Δ9-THC environment, the undesirable effects of 99-THC are reduced, which improves its safety profile.
"Relatively recently, multidirectional biological effects have been demonstrated in various preclinical models, including the antioxidant and anti-inflammatory effects of cannabidiol."
"Important in CBD therapeutic applications is the lack of psychotropic effects. Furthermore, this phytocannabinoid is not teratogenic or mutagenic. Until recently, CBD was thought to have only low toxicity to humans and other species, but recent studies indicate an increase in ALT and AST levels after CBD treatment, which disqualifies it as the drug of choice.
CBD molecular structure
"In addition, it has been found that CBD may interfere with the hepatic metabolism of some drugs by inactivating cytochrome P450 3A and P450 2C. Such interactions should be considered when co-administering CBD with other drugs metabolized by above enzymes.
"In order to find compounds with a greater therapeutic profile and activity than CBD, without any adverse effects, the biological properties of both natural and synthetic CBD derivatives were checked, with the hope of finding the perfect derivative that provides a close to ideal therapeutic effect."
View the original study.
🎧 Like what you just read? Listen and learn with our highly educational weekly Cannabis Commerce + Chemistry Podcast. At under 30 minutes per episode, it helps industry professionals stay current on trending topics.